• Facebook
  • Twitter
ImmunityBio
  • HOME
  • ABOUT
  • SCIENCE
  • NEWS
    • PRESS RELEASES
    • EVENTS
  • CAREERS
  • CONTACT
  • EXPANDED ACCESS
Select Page

ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spread

Jan 19, 2021 | Press Releases

Plans to study COVID-19 subcutaneous and oral, room-temperature capsule vaccineto protect against escape mutants ImmunityBio to conduct initial trial of its human adenovirus (hAd5) COVID-19 vaccine candidate in South Africa, where the 501Y.V2 strain has been recently...

NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials

Jan 13, 2021 | Press Releases

Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment options In initial Cancer Moonshot QUILT trials of haNK and avelumab...

NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021

Jan 6, 2021 | Press Releases

EL SEGUNDO, Calif., January 6, 2021 — NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executive Chairman of the Board of Directors, will participate in the 39th Annual...

ImmunityBio Simulates SARS-CoV-2 Spike Protein Binding Using Molecular Dynamics

Jan 4, 2021 | Press Releases

Detailed computer modeling, completed in partnership with Microsoft, explains virulence of COVID-19 and provides key information that may lead to a better understanding of the multiple mutations currently occurring to the “spike” protein as the virus evolves...

ImmunityBio Appoints Fabio M. Benedetti, M.D. as Chief Strategy Officer

Dec 30, 2020 | Press Releases

Dr. Benedetti Brings More Than 20 Years in Oncology Clinical Development and Global Large Pharma Experience  CULVER CITY, Calif., December 30, 2020 – ImmunityBio, Inc., a privately-held immunotherapy company, today announced that it has appointed Fabio M. Benedetti,...

ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate

Dec 21, 2020 | Press Releases

QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort with 59% probability of patients maintaining complete response for at least 12 months Over 85% of patients in this study have avoided a cystectomy to date...
« Older Entries
Next Entries »

Categories

Press Releases
Events

Archives

Copyright © ImmunityBio, Inc. All Right Reserved - Privacy | Terms of Use
This website uses cookies which may passively collect and share information about your site use, and may allow you to actively submit information to us through fillable forms, as described in and subject to our Privacy Policy.
By continuing to use this website or clicking the “agree” button below, you agree to our Terms of Use and Privacy Policy and consent to our processing of personal information as described therein.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT